Scarica l'app Stockscreener
4.015
1.69%
0.025
Prime Medicine Inc Borsa (PRME) Ultime notizie
Here’s Why H.C. Wainwright Upgraded Prime Medicine (PRME) To “Buy” - Yahoo Finance
10 Overlooked Penny Stocks to Buy Right Now - Insider Monkey
PRMEPrime Medicine Inc Options - Finviz
Enterprise value to revenue forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
PRME Q1 2026 Earnings: EPS Misses Estimates but Stock Gains on Pipeline ProgressEarnings Decline Risk - dars.gov.et
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 2500 Growth Benchmark - marketscreener.com
Price to book forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
Prime Medicine, Inc.(NasdaqGM:PRME) added to Russell Microcap Growth Benchmark Index - marketscreener.com
H.C. Wainwright upgrades Prime Medicine stock rating to buy By Investing.com - Investing.com Australia
H.C. Wainwright upgrades Prime Medicine stock rating to buy - Investing.com
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 2000 Growth Benchmark - marketscreener.com
H.C. Wainwright Upgrades Prime Medicine(PRME.US) to Buy Rating, Announces Target Price $8 - Moomoo
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 3000E Growth Benchmark - marketscreener.com
Prime Medicine, Inc.(NasdaqGM:PRME) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Prime Medicine, Inc. Actuals & Estimates (NASDAQ:PRME) - TradingView
PRME Forecast — Price Target — Prediction for 2027 - TradingView
Prime Medicine Inc (PRME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prime Medicine (PRME) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine Says PM359 Granted US FDA Regenerative Medicine Advanced Therapy Designation - Moomoo
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) - marketscreener.com
Prime Medicine Receives U.S. FDA Regenerative Medicine - GlobeNewswire
Citizens reiterates Prime Medicine stock rating on gene therapy focus By Investing.com - Investing.com South Africa
Citizens reiterates Prime Medicine stock rating on gene therapy focus - Investing.com
Prime Medicine, Inc. (PRME) reports Q1 loss, misses revenue estimates - MSN
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL) - The Globe and Mail
Prime Medicine’s PM-577a cleared for clinic for Wilson’s disease - BioWorld News
Prime Medicine receives clearance for first in vivo gene therapy trial - Investing.com Canada
Prime Medicine receives clearance for first in vivo gene therapy trial By Investing.com - Investing.com India
Prime Medicine Announces New Zealand Clearance of Clinical - GlobeNewswire
Prime Medicine Inc (PRME) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocular Therapeutix vs Prime Medicine: Two Paths in Medical Innovation - HarianBasis.co
Prime Medicine Inc (PRME) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prime Medicine Inc (PRME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Prime Medicine Inc (PRME) Institutional Confidence - TradingKey
Prime Medicine Inc (PRME) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation StocksNews and Statistics - IndexBox
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
PRME Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Development ProgramsEPS Guidance Update - newsline.com
Prime Medicine's Prime Editing Is Worth The Risk (NASDAQ:PRME) - Seeking Alpha
Prime Drink Group announces private placement up to C$2.2M By Investing.com - Investing.com Australia
Prime Drink Group announces private placement up to C$2.2M - Investing.com UK
Prime Medicine (PRME) Holds Steady Near Support as Gene Editing Stock Seeks DirectionBlue Chip Entry Points - newsline.com
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Transcript : Prime Medicine, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
Prime Medicine Stockholders Reaffirm Board and Auditor Choices - The Globe and Mail
Prime Medicine (PRME) awards director David Schenkein 75,000 stock options - Stock Titan
Prime Medicine (PRME) director receives 75,000 options at $3.06 - Stock Titan
Prime Medicine (PRME) director and 10% owner receives 75,000-share option grant - Stock Titan
1.53%
3.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):